On 15 June the GI Cancer Institute held an instalment of the Living Room Series in Sydney. Two leading Australian researchers spoke about the latest developments that could change treatment for gastro-intestinal cancers. They shared these insights on their return from the largest cancer research conference in the world, the American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago.
It was exciting to hear that there is so much new research that can give patients more options and better treatments.
In colorectal cancer, Professor Chris Karapetis shared the latest research into when it could be effective to use a combination of chemotherapy drugs rather than one in locally advanced rectal cancer. Another study has found that some patients could potentially forgo the side effects of heated abdomen chemotherapy. The AGITG has also conducted a substudy that looked at how patients weighed up the decision to take on a longer course of chemotherapy.
In pancreatic cancer, Dr Katrin Sjoquist said, “We’ve got lots of potential new treatments straight away, which is encouraging.” Researchers looked at the important question of the best time and type of chemotherapy to be given to pancreatic cancer patients.
There was also insight into oesophageal cancer prevention – people with a pre-disposition could reduce their risk of oesophageal cancer by taking a combination of aspirin and a proton pump inhibitor.
A lot of information was presented – you can watch the presentations below:
- 05:10:Prof Karapetis on colorectal cancer
- 36:16:Dr Sjoquist on pancreatic cancer
- 53:15:Dr Sjoquist on gastric and gastro-oesophageal cancer